Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-fallypride
- Development stage
- Phase 2
- Lead developer
- University of California, Irvine
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
18F-fallypride is a high-affinity radiopharmaceutical PET imaging agent that targets dopamine D2 and D3 receptors (D2/D3R). Developed and extensively studied by researchers at the University of California, Irvine, it is a small molecule radiotracer labeled with the radioisotope fluorine-18. It is primarily utilized in clinical research to visualize both striatal and extrastriatal dopamine receptors in the brain, facilitating the study of various neurological and psychiatric disorders such as schizophrenia, Parkinson's disease, Alzheimer's disease, and substance addiction. Beyond neuroimaging, 18F-fallypride has been investigated as a non-invasive tool for monitoring pancreatic beta-cell mass in patients with Type 1 Diabetes Mellitus, as these cells also express D2 receptors. It is used as a diagnostic research tool rather than a therapeutic agent.
- Other names
- fallyprideFluorine-18 fallyprideFluorine18 fallyprideFluorine 18 fallypride(S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2,3-dimethoxybenzamide
02
Targets
DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)
Beyond the preview
Go deeper on 18F-fallypride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-fallypride.